Interferons as Therapeutic Agents for Infectious Diseases

被引:25
作者
Bergman, Scott J. [1 ,2 ]
Ferguson, McKenzie C. [2 ]
Santanello, Cathy [3 ]
机构
[1] So Illinois Univ, Sch Med, Div Infect Dis, Edwardsville, IL 62026 USA
[2] So Illinois Univ Edwardsville, Dept Pharm Practice, Sch Pharm, Edwardsville, IL 62026 USA
[3] So Illinois Univ Edwardsville, Sch Pharm, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA
关键词
Interferon-alpha; Viral hepatitis; Respiratory tract infection viruses; Common cold; Human papillomavirus; Genital warts; Vaccine; Adjuvant; HEPATITIS-C VIRUS; RECURRENT RESPIRATORY PAPILLOMATOSIS; HUMAN-PAPILLOMAVIRUS; ALBINTERFERON ALPHA-2B; RHINOVIRUS INFECTION; INTRANASAL INTERFERON-ALPHA-2B; ANTIVIRAL ACTIVITY; GENETIC-VARIATION; RANDOMIZED-TRIAL; I INTERFERON;
D O I
10.1016/j.idc.2011.07.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This article explains the rationale for development of interferons as therapeutic agents, and describes commercial products available today. It also provides a summary of studies that have been performed with interferons for use as exogenous biological response modifiers in viral infections. Overall, the best data exist for treatment of viral hepatitis B and C, for which interferons are a cornerstone of therapy. Although infections with human papillomavirus and common cold viruses sometimes respond favorably to interferons, their outcomes are far from ideal. Finally, the role of interferons as vaccine adjuvants is still being explored but could be promising.
引用
收藏
页码:819 / +
页数:17
相关论文
共 102 条
  • [1] Hepatitis C Pharmacogenetics: State of the Art in 2010
    Afdhal, Nezam H.
    McHutchison, John G.
    Zeuzem, Stefan
    Mangia, Alessandra
    Pawlotsky, Jean-Michel
    Murray, Jeffrey S.
    Shianna, Kevin V.
    Tanaka, Yasuhito
    Thomas, David L.
    Booth, David R.
    Goldstein, David B.
    [J]. HEPATOLOGY, 2011, 53 (01) : 336 - 345
  • [2] Alston B, 1999, J ACQ IMMUN DEF SYND, V22, P348
  • [3] [Anonymous], MIMS MED MICROBIOLOG
  • [4] [Anonymous], GEN HPV INF FACT SHE
  • [5] AOKI FA, 2010, PRINCIPLES PRACTICES, V1, P565
  • [6] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    Bacon, Bruce R.
    Gordon, Stuart C.
    Lawitz, Eric
    Marcellin, Patrick
    Vierling, John M.
    Zeuzem, Stefan
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Boparai, Navdeep
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Esteban, Rafael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) : 1207 - 1217
  • [7] Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients
    Bain, Vincent G.
    Kaita, Kelly D.
    Marotta, Paul
    Yoshida, Eric M.
    Swain, Mark G.
    Bailey, Robert J.
    Patel, Keyur
    Cronin, Patrick W.
    Pulkstenis, Erik
    McHutchison, John G.
    Subramanian, G. Mani
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (06) : 701 - 706
  • [8] Human Papillomaviruses and the Interferon Response
    Beglin, Melanie
    Melar-New, Marta
    Laimins, Laimonis
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2009, 29 (09) : 629 - 635
  • [9] BERGMAN SJ, CLIN MICROB IN PRESS
  • [10] Boceprevir, an NS3 Protease Inhibitor of HCV
    Berman, Kenneth
    Kwo, Paul Y.
    [J]. CLINICS IN LIVER DISEASE, 2009, 13 (03) : 429 - +